Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
HeartFlow offers a groundbreaking, non-invasive cardiac test that delivers detailed visualizations of individual coronary arteries, allowing doctors to develop more tailored treatment strategies for their patients. The process begins when a patient has a standard coronary computed tomography scan performed at a medical facility. Following this scan, the CT images are securely sent to our cloud-based system. Utilizing cutting-edge algorithms powered by artificial intelligence, we create a customized digital representation of the patient's coronary arteries. Our skilled analysts then review this model, making necessary adjustments to ensure accuracy. After finalizing the patient-specific model, the HeartFlow pathway employs physiological principles and computational fluid dynamics to analyze blood flow and compute FFRCT values throughout the model. We adhere to strict and well-established protocols throughout this entire process, ensuring uniform processing for every individual patient, which ultimately enhances the quality of care provided. This innovative approach not only improves diagnostic precision but also empowers healthcare providers to make informed decisions for optimal patient outcomes.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
HeartFlow
Founded
2010
Country
United States
Website
www.heartflow.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/
Product Features
Medical Imaging
Automated Routing
No
Comparison View
No
Compliance Management
No
Data Import / Export
No
Diagnostic Reporting
No
Image Analytics
No
Treatment Planning
No
Workflow Management
No